First sublingual immunotherapy tablet for house dust mite allergic rhinitis may be U.S.-bound
March 9, 2016|Internal Medicine
Author and Disclosure Information
AT 2016 AAAAI ANNUAL MEETING
Merck already has two FDA-approved SLIT tablets developed with ALK on the U.S. market: Grastek, for treatment of grass pollen–induced allergic rhinitis in children and adults, and Ragwitek, for ragweed-induced allergic disease in adults.
The trial was sponsored by Merck and presented by a full-time company employee.
